stockrow
Friday 6 November 2026
Export SXTC’s income statement to Excel — free account
China SXT Pharmaceuticals, Inc.
SXTC Healthcare Drug Manufacturers Specialty & Generic
China SXT Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 million, down 34.6% from fiscal 2025.
2.92
0.01
−0.34%
Follow SXTC
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to March
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | 5 | 7 | 7 | 5 | 5 | 3 | 2 | 2 | 2 | 1 | (14.9%) | — | — | — | — | |
| Gross margin, % | 47.36 | 48.46 | 65.77 | 52.37 | 59.44 | 48.10 | 21.62 | 28.73 | 21.10 | 21.85 | (25.5) pt | ||||||
| EBT | 2 | 2 | 2 | (10) | (3) | (5) | (6) | (3) | (3) | (6) | n/m | ||||||
| EBT margin, % | 32.37 | 23.19 | 25.55 | (201.26) | (61.56) | (207.81) | (301.00) | (160.67) | (189.77) | (545.22) | (577.6) pt | ||||||
| Net income | 1 | 1 | 2 | (10) | (3) | (6) | (6) | (3) | (3) | (6) | n/m | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | 0.24 | 0.35 | 0.34 | 0.84 | 6.64 | 2.50 | 7.38 | 17.86 | 0.00 | 11,381.00 | +230.2% | |||||
| Earnings | 0.06 | 0.06 | 0.07 | (1.66) | (3.82) | (5.52) | (22.23) | (28.69) | (27,852.60) | (73,043.96) | n/m | ||||||
| Cash flow | 0.01 | 0.10 | 0.01 | 0.15 | (1.83) | 0.26 | (0.30) | (17.85) | 0.00 | (40,175.00) | n/m | ||||||
| Capex | (0.01) | (0.05) | (0.03) | (0.07) | (0.13) | (0.06) | (0.26) | (0.07) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | 0.01 | 0.04 | (0.02) | 0.09 | (1.96) | 0.20 | (0.57) | (17.92) | 0.00 | (40,175.00) | n/m | ||||||
| Book value | 0.09 | 0.16 | 0.54 | 1.52 | 22.18 | 15.79 | 55.02 | 128.99 | 0.00 | 297,074.00 | +428.3% | ||||||
| Shares, m | 20 | 20 | 21 | 6 | 1 | 1 | 0 | 0 | 0 | 0 | (74.2%) | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | 143.50 | 143.50 | 101.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 38.8 | |||||
| P/S | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| P/B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | 0.00 | 0.00 | 0.00 | (0.05) | (1.34) | (1.83) | (3.04) | (2.11) | (3.79) | (5.94) | (1.8) | ||||||
| EV/FCF | 0.00 | 0.00 | (3.72) | 0.18 | 3.73 | 6.79 | 16.41 | 2.93 | 2.80 | 2.90 | 3.2 | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | 0 | 2 | 0 | 1 | (1) | 0 | 0 | (2) | (2) | (4) | n/m | |||||
| Capex | 0 | (1) | (1) | 0 | 0 | 0 | 0 | 0 | 0 | — | n/m | ||||||
| Free cash flow | 0 | 1 | 0 | 1 | (1) | 0 | 0 | (2) | (2) | (4) | n/m | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | 1 | 2 | 9 | 7 | 5 | 5 | 5 | 5 | 15 | 30 | +41.5% | |||||
| Net debt | 0 | 0 | (9) | (1) | (13) | (14) | (14) | (10) | (17) | (27) | n/m | ||||||
| Shareholders’ equity | 2 | 3 | 11 | 9 | 16 | 16 | 15 | 14 | 15 | 30 | +36.1% | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | 20.21 | 18.15 | 12.25 | (52.53) | (9.77) | (16.85) | (18.81) | (11.76) | (14.75) | (22.00) | (42.2) pt | |||||
| ROIC | 47.93 | 33.86 | 58.66 | (9.48) | (51.90) | (111.79) | (453.09) | (36.86) | 0.00 | (175.91) | (223.8) pt | ||||||
| ROE | 91.32 | 46.22 | 21.39 | (100.32) | (21.67) | (35.42) | (38.15) | (21.65) | (22.50) | (27.49) | (118.8) pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | 105 | 96 | 97 | 96 | 87 | 78 | 75 | 75 | 56 | (7.6%) | |||||
| Revenue/emp, $m | 0.00 | 0.07 | 0.07 | 0.05 | 0.05 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Mar 2026 · latest quarter Jan 0001 · fundamentals updated 2 Nov 2026
China SXT Pharmaceuticals, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| APUS Apimeds Pharmaceuticals US, Inc. | $4.1M | — (loss-making) | — | — | n/m | −67.94% (below 0%: shrinking) | — | 0.00% | Compare |
| RDHL Redhill Biopharma Ltd. | $3.8M | — (loss-making) | — (loss-making) | −90.32% (below 0%: shrinking) | n/m | −107.31% (below 0%: shrinking) | (7.52%) | 0.00% | Compare |
| BTAIQ BioXcel Therapeutics, Inc. | $2.3M | — (loss-making) | — (loss-making) | +51.67% (above 0%: growing) | n/m | +51.51% (above 0%: growing) | 87.91% | (5,600.55%) | Compare |
| PRFX PainReform Ltd. | $2.3M | — (loss-making) | — (loss-making) | — | n/m | +52.56% (above 0%: growing) | 0.00% | 0.00% | Compare |
| AKAN Akanda Corp. | $2.2M | — | — | — | — | −472.01% (below 0%: shrinking) | (197.87%) | 0.00% | Compare |
| SBFM Sunshine Biopharma, Inc. | $2.1M | — (loss-making) | — (loss-making) | −1.56% (below 0%: shrinking) | n/m | +49.38% (above 0%: growing) | 26.20% | (17.41%) | Compare |
| SXTC China SXT Pharmaceuticals, Inc. | $2.0M | — (loss-making) | — (loss-making) | −16.76% (below 0%: shrinking) | +92.67% (above 0%: growing) | −107.59% (below 0%: shrinking) | 44.09% | 0.00% | |
| PTPI Petros Pharmaceuticals, Inc. | $1.0M | — (loss-making) | — (loss-making) | +299.12% (above 0%: growing) | n/m | +71.27% (above 0%: growing) | 359.80% | 0.00% | Compare |
| IMCC IM Cannabis Corp. | $980.0K | — (loss-making) | — (loss-making) | −40.28% (below 0%: shrinking) | n/m | −266.81% (below 0%: shrinking) | 19.83% | (27.54%) | Compare |
| Median of peers | $2.3M | — | — | −1.56% | — | −9.28% | 19.83% | 0.00% |